Prostate cancer: Prognostic significance of the association of heterogeneous nuclear ribonucleoprotein K and androgen receptor expression

International Journal of Oncology

Volumn 44, Issue 5, 2014, Pages 1589-1598

  Barboro, Paola ^a   Salvi, Sandra ^a   Rubagotti, Alessandra ^a   Boccardo, Simona ^a   Spina, Bruno ^a   Truini, Mauro ^a   Carmignani, Giorgio ^a   Introini, Carlo ^a   Ferrari, Nicoletta ^a   Boccardo, Francesco ^a   Balbi, Cecilia ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Androgen receptor; Diagnostic and prognostic biomarkers; Heterogeneous nuclear ribonucleoprotein K; Immunohistochemistry; Prognosis; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN K; MITOGEN ACTIVATED PROTEIN KINASE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BIOCHEMICAL FAILURE FREE SURVIVAL; CANCER CELL; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CELL POPULATION; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

AGED; CELL LINE, TUMOR; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEIN K; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PHOSPHORYLATION; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84899094362     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2345     Document Type: Article

References (48)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
2. Stamey TA: Preoperative serum prostate-specific antigen (PSA) below 10 μg/l predicts neither the presence of prostate cancer nor the rate of postoperative PSA failure. Clin Chem 47: 631-634, 2001.
3. Bostwick DG, Grignon DJ, Hammond ME, Amin MB, Cohen M, Crawford D, Gospadarowicz M, Kaplan RS, Miller DS, Montironi R, Pajak TF, Pollack A, Srigley JR and Yarbro JW: Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124: 995-1000, 2000. (Pubitemid 30602040)
4. Humphrey PA and Vollmer RT: Percentage carcinoma as a measure of prostatic tumor size in radical prostatectomy tissues. Mod Pathol 10: 326-333, 1997. (Pubitemid 27228880)
5. Tefilli MV, Gheiler EL, Tiguert R, Sakr W, Grignon DJ, Banerjee M, Pontes JE and Wood DP Jr: Should Gleason score 7 prostate cancer be considered a unique grade category? Urology 53: 372-377, 1999. (Pubitemid 29063329)
6. Montironi R, Mazzuccheli R, Scarpelli M, Lopez-Beltran A, Fellegara G and Algaba F: Gleason grading of prostate cancer in needle biopsies or radical prostatectomy specimens: contemporary approach, current clinical significance and sources of pathology discrepancies. BJU Int 95: 1146-1152, 2005. (Pubitemid 40799472)
7. Mukhopadhyay NK, Kim J, Cinar B, Ramachandran A, Hager MH, Di Vizio D, Adam RM, Rubin MA, Raychaudhuri P, De Benedetti A and Freeman MR: Heterogeneous nuclear ribonucleoprotein K is a novel regulator of androgen receptor translation. Cancer Res 69: 2210-2218, 2009.
8. Barboro P, Repaci E, Rubagotti A, Salvi S, Boccardo S, Spina B, Truini M, Introini C, Puppo P, Ferrari N, Carmignani G, Boccardo F and Balbi C: Heterogeneous nuclear ribonucleoprotein K: altered pattern of expression associated with diagnosis and prognosis of prostate cancer. Br J Cancer 100: 1608-1616, 2009.
9. Bomsztyk K, Denisenko O and Ostrowski J: hnRNP K: one protein multiple processes. Bioessays 26: 629-638, 2004. (Pubitemid 38758340)
10. Ostrowski J and Bomsztyk K: Nuclear shift of hnRNP K protein in neoplasms and other states of enhanced cell proliferation. Br J Cancer 89: 1493-1501, 2003. (Pubitemid 37386605)
11. Carpenter B, MacKay C, Alnabulsi A, MacKay M, Telfer C, Melvin WT and Murray GI: The roles of heterogeneous nuclear ribonucleoproteins in tumour development and progression. Biochim Biophys Acta 1765: 85-100, 2006.
12. Carpenter B, McKay M, Dundas SR, Lawrie LC, Telfer C and Murray GI: Heterogeneous nuclear ribonucleoprotein K is over expressed, aberrantly localized and is associated with poor prognosis in colorectal cancer. Br J Cancer 95: 921-927, 2006. (Pubitemid 44498109)
13. Chen LC, Hsueh C, Tsang NM, Liang Y, Chang KP, Hao SP, Yu JS and Chang YS: Heterogeneous nuclear ribonucleoprotein K and thymidine phosphorylase are independent prognostic and therapeutic markers for nasopharyngeal carcinoma. Clin Cancer Res 14: 3807-3813, 2008.
14. Matta A, Tripathi SC, DeSouza LV, Grigull J, Kaur J, Chauhan SS, Srivastava A, Thakar A, Shukla NK, Duggal R, DattaGupta S, Ralhan R and Siu KWM: Heterogeneous ribonucleoprotein K is a marker of oral leukoplakia and correlates with poor prognosis of squamous cell carcinoma. Int J Cancer 125: 1398-1406, 2009.
15. Chen LC, Chung IC, Hsueh C, Tsang NM, Chi LM, Liang Y, Chen CC, Wang LJ and Chang YS: The antiapoptotic protein FLIP, is regulated by heterogeneous nuclear ribonucleoprotein K and correlates with poor overall survival of nasopharyngeal carcinoma patients. Cell Death Differ 17: 1463-1473, 2010.
16. Wen F, Shen A, Shanas R, Bhattacharyya A, Lian F, Hostetter G and Shi J: Higher expression of the heterogeneous nuclear ribonucleoprotein K in melanoma. Ann Surg Oncol 17: 2619-2627, 2010.
17. Hope NR and Murray GI: The expression profile of RNA-binding proteins in primary and metastatic colorectal cancer: relationship of heterogeneous nuclear ribonucleoproteins with prognosis. Human Pathol 42: 392-402, 2011.
18. Wang F, Zhang P, Shi C, Yang Y and Qin H: Immunohistochemical detection of HSP27 and hnRNP K as prognostic and predictive biomarkers for colorectal cancer. Med Oncol 29: 1780- 1788, 2012.
19. Nagano K, Masters JR, Akpan A, Yang A, Corless S, Wood C, Hastie C, Zvelebil M, Cramer R and Naaby-Hansen S: Differential protein synthesis and expression levels in normal and neoplastic human prostate cells and their regulation by type I and II interferons. Oncogene 23: 1693-1703, 2004. (Pubitemid 38445161)
20. Wang LG, Johnson EM, Kinoshita Y, Babb JS, Buckley MT, Liebes LF, Melamed J, Liu XM, Kurek R, Ossowski L and Ferrari AC: Androgen receptor overexpression in prostate cancer linked to Purα loss from a novel repressor complex. Cancer Res 68: 2678-2688, 2008. (Pubitemid 351556265)
21. Boccardo F, Rubagotti A, Carmignani G, Romagnoli A, Nicolò G, Barboro P, Parodi S, Patrone E and Balbi C: Nuclear matrix proteins changes in cancerous prostate tissues and their prognostic value in clinically localized prostate cancer. Prostate 55: 259-264, 2003. (Pubitemid 36618184)
22. Ricci F, Rubagotti A, Zinoli L, Mangerini R, Nuzzo PV, Carmignani G, Simonato A, Barboro P, Balbi C and Boccardo F: Prognostic value of nuclear matrix protein expression in localized prostate cancer. J Cancer Res Clin Oncol 138: 1379-1384, 2012.
23. Barboro P, Repaci E, Ferrari N, Rubagotti A, Boccardo F and Balbi C: Androgen receptor and heterogeneous nuclear ribonucleoprotein K colocalize in the nucleoplasm and are modulated by bicalutamide and 4-hydroxy-tamoxifen in prostatic cancer cell lines. Prostate 71: 1466-1479, 2011.
24. Igawa T, Lin FF, Lee MS, Karan D, Batra SK and Lin MF: Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model. Prostate 50: 222-235, 2002. (Pubitemid 34184661)
25. Tepper CG, Boucher DL, Ryan PE, Ma AH, Xia L, Lee LF, Pretlow TG and Kung HJ: Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res 62: 6606-6614, 2002. (Pubitemid 35364127)
26. Barboro P, Rubagotti A, Orecchia P, Spina B, Truini M, Repaci E, Carmignani G, Romagnoli A, Introini C, Boccardo F, Carnemolla B and Balbi C: Differential proteomic analysis of nuclear matrix in muscle-invasive bladder cancer: potential to improve diagnosis and prognosis. Cell Oncol 30: 13-26, 2008. (Pubitemid 351161036)
27. Kim D, Gregory CW, Smith GJ and Mohler JL: Immunohistochemical quantitation of androgen receptor expression using color video image analysis. Cytometry 35: 2-10, 1999. (Pubitemid 29031186)
28. Fleiss JL: Statistical Methods for Rates and Proportions. 2nd edition. John Wiley & Sons, Inc., New York, 1981.
29. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
30. Cox DR: Regression models and life tables. JR Stat Soc B 34: 187-220, 1972.
31. Armitage P, Berry G and Matthews JNS: Statistical methods in Medical Research. 4th edition. Blackwell Publishing, Oxford, 2000.
32. Heinlein CA and Chang C: Androgen receptor in prostate cancer. Endocr Rev 25: 276-308, 2004. (Pubitemid 38501396)
33. Mohler JM: A role for the androgen-receptor in clinically localized and advanced prostate cancer. Best Pract Res Clin Endocrinol Metab 22: 357-372, 2008.
34. Habelhah H, Shah K, Huang L, Ostareck-Lederer A, Burlingame AL, Shokat KM, Hentze MW and Ronai Z: ERK phosphorylation drives cytoplasmic accumulation of hnRNP-K and inhibition of mRNA translation. Nat Cell Biol 3: 325-330, 2001. (Pubitemid 32201331)
35. Hong SK, Jeong JH, Chan AM and Park JI: AKT upregulates B-Raf Ser445 phosphorylation and ERK1/2 activation in prostate cancer cells in response to androgen depletion. Exp Cell Res 319: 1732-1743, 2013.
36. Fiorentino M, Capizzi E and Loda M: Blood and tissue biomarkers in prostate cancer: State of the art. Urol Clin North Am 37: 131-141, 2010.
37. Sadi M and Barrack ER: Image analysis of androgen receptor immunostaining in metastatic prostate cancer. Heterogeneity as a predictor of response to hormonal therapy. Cancer 71: 2574-2580, 1993. (Pubitemid 23100494)
38. Magi-Galluzzi C, Xu X, Hlatky L, Hahnfeldt P, Kaplan I, Hsiao P, Chang C and Loda M: Heterogeneity of androgen receptor content in advanced prostate cancer. Mod Pathol 10: 8398-8445, 1997.
39. Mikula M and Ostrowski J: HNRNP K (heterogeneous nuclear ribonucleoprotein K). Atlas Genet Cytogenet Oncol Haematol 14: 127-129, 2010.
40. Shi L, Ko S, Kim S, Echchgadda I, Oh TS, Song CS and Chatterjee B: Loss of androgen receptor in aging and oxidative stress through Myb protooncoprotein-regulated reciprocal chromatin dynamics of p53 and poly(ADP-ribose) polymerase PARP-1. J Biol Chem 283: 36474-36485, 2008.
41. Inoue A, Sawata SY, Taira K and Wadhwa R: Loss-of-function screening by randomized intracellular antibodies: identification of hnRNP-K as a potential target for metastasis. Proc Natl Acad Sci USA 104: 8983-8988, 2007. (Pubitemid 47175423)
42. Benelli R, Monteghirfo S, Balbi C, Barboro P and Ferrari N: Novel antivascular efficacy of metronomic docetaxel therapy in prostate cancer: hnRNP K as a player. Int J Cancer 124: 2989-2996, 2009.
43. Paliouras M, Zaman N, Lumbroso R, Kapogeorgakis L, Beitel LK, Wang E and Trifiro M: Dynamic rewiring of the androgen receptor protein interaction network correlates with prostate cancer clinical outcomes. Integr Biol 3: 1020-1032, 2011.
44. Chmelar R, Buchanan G, Need EF, Tilley W and Greenberg NM: Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int J Cancer 120: 719-733, 2007. (Pubitemid 46175390)
45. Barboro P, Borzì L, Repaci E, Ferrari N and Balbi C: Androgen Receptor activity is affected by both nuclear matrix localization and the phosphorylation status of the heterogeneous nuclear ribonucleoprotein K in anti-androgen-treated LNCaP cells. PLoS One 8: e79212, 2013.
46. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM and Franklin RA: Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773: 1263-1284, 2007. (Pubitemid 47125967)
47. Ciarlo M, Benelli R, Barbieri O, Minghelli S, Barboro P, Balbi C and Ferrari N: Regulation of neuroendocrine differentiation by AKT/hnRNPK/AR/β- catenin signaling in prostate cancer cells. Int J Cancer 131: 582-590, 2012.
48. Gao R, Yu Y, Inoue A, Widodo N, Kaul SC and Wadhwa R: Heterogeneous nuclear ribonucleoprotein K (hnRNP-K) promotes tumor metastasis by induction of genes involved in extracellular matrix, cell movement, and angiogenesis. J Biol Chem 288: 15046-15056, 2013.